Endometrial Cancer - Pipeline Review, H2 2016
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer – Pipeline Review, H2 2016, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.
Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 35, 17, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.Endometrial Cancer.
Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table Of Contents
Table of Contents
Table of Contents 2
Introduction 6
Endometrial Cancer Overview 7
Therapeutics Development 8
Endometrial Cancer - Therapeutics under Development by Companies 10
Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 13
Endometrial Cancer - Pipeline Products Glance 14
Endometrial Cancer - Products under Development by Companies 17
Endometrial Cancer - Products under Investigation by Universities/Institutes 21
Endometrial Cancer - Companies Involved in Therapeutics Development 22
Endometrial Cancer - Therapeutics Assessment 67
Drug Profiles 83
Endometrial Cancer - Dormant Projects 384
Endometrial Cancer - Discontinued Products 387
Endometrial Cancer - Product Development Milestones 388
Appendix 403
List Of Tables
List of Tables
Number of Products under Development for Endometrial Cancer, H2 2016 16
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Number of Products under Development by Companies, H2 2016 (Contd..1) 19
Number of Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Comparative Analysis by Late Stage Development, H2 2016 22
Comparative Analysis by Clinical Stage Development, H2 2016 23
Comparative Analysis by Early Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Development by Companies, H2 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Endometrial Cancer - Pipeline by Ability Pharmaceuticals, S.L., H2 2016 30
Endometrial Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 31
Endometrial Cancer - Pipeline by Aeterna Zentaris Inc., H2 2016 32
Endometrial Cancer - Pipeline by ArQule, Inc., H2 2016 33
Endometrial Cancer - Pipeline by AstraZeneca Plc, H2 2016 34
Endometrial Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 35
Endometrial Cancer - Pipeline by BeiGene, Ltd., H2 2016 36
Endometrial Cancer - Pipeline by BioNTech AG, H2 2016 37
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 38
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 39
Endometrial Cancer - Pipeline by Cellceutix Corporation, H2 2016 40
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 41
Endometrial Cancer - Pipeline by Eisai Co., Ltd., H2 2016 42
Endometrial Cancer - Pipeline by Eli Lilly and Company, H2 2016 43
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 44
Endometrial Cancer - Pipeline by Exelixis, Inc., H2 2016 45
Endometrial Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 46
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H2 2016 47
Endometrial Cancer - Pipeline by GamaMabs Pharma S.A., H2 2016 48
Endometrial Cancer - Pipeline by Genmab A/S, H2 2016 49
Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 50
Endometrial Cancer - Pipeline by Gradalis Inc., H2 2016 51
Endometrial Cancer - Pipeline by Horizon Pharma Plc, H2 2016 52
Endometrial Cancer - Pipeline by Immunocore Ltd, H2 2016 53
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H2 2016 54
Endometrial Cancer - Pipeline by Incyte Corporation, H2 2016 55
Endometrial Cancer - Pipeline by Innate Pharma S.A., H2 2016 56
Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 57
Endometrial Cancer - Pipeline by Merck & Co., Inc., H2 2016 58
Endometrial Cancer - Pipeline by Merck KGaA, H2 2016 59
Endometrial Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 60
Endometrial Cancer - Pipeline by Novartis AG, H2 2016 61
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H2 2016 62
Endometrial Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 63
Endometrial Cancer - Pipeline by Pfizer Inc., H2 2016 64
Endometrial Cancer - Pipeline by Pharma Mar, S.A., H2 2016 65
Endometrial Cancer - Pipeline by Pharmsynthez, H2 2016 66
Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H2 2016 67
Endometrial Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016 68
Endometrial Cancer - Pipeline by Sanofi, H2 2016 69
Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd, H2 2016 70
Endometrial Cancer - Pipeline by Sigma-Tau S.p.A., H2 2016 71
Endometrial Cancer - Pipeline by Synthon Holdings BV, H2 2016 72
Endometrial Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 73
Endometrial Cancer - Pipeline by Vyriad Inc, H2 2016 74
Assessment by Monotherapy Products, H2 2016 75
Assessment by Combination Products, H2 2016 76
Number of Products by Stage and Target, H2 2016 78
Number of Products by Stage and Mechanism of Action, H2 2016 83
Number of Products by Stage and Route of Administration, H2 2016 88
Number of Products by Stage and Molecule Type, H2 2016 90
Endometrial Cancer - Dormant Projects, H2 2016 392
Endometrial Cancer - Dormant Projects (Contd..1), H2 2016 393
Endometrial Cancer - Dormant Projects (Contd..2), H2 2016 394
Endometrial Cancer - Discontinued Products, H2 2016 395
List Of Figures
List of Figures
Number of Products under Development for Endometrial Cancer, H2 2016 16
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 23
Comparative Analysis by Early Stage Products, H2 2016 24
Assessment by Monotherapy Products, H2 2016 75
Assessment by Combination Products, H2 2016 76
Number of Products by Top 10 Targets, H2 2016 77
Number of Products by Stage and Top 10 Targets, H2 2016 77
Number of Products by Top 10 Mechanism of Actions, H2 2016 82
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 82
Number of Products by Top 10 Routes of Administration, H2 2016 87
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 87
Number of Products by Top 10 Molecule Types, H2 2016 89
Number of Products by Stage and Top 10 Molecule Types, H2 2016 89
